N-[2-[cyclohexyl(methyl)amino]ethyl]-4-[(E)-[4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: N-[2-[cyclohexyl(methyl)amino]ethyl]-4-[(E)-[4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide
• 化学式: C₃₃H₃₇N₃O₂S
• 分子量: 539.7
• InChiKey: YLXLXNLFYCLDAU-DFKUXCBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：VM Pharma LLC

  公开号：US20140228331A1

  公开（公告）日：2014-08-14

  The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.

  本发明涉及一种新型合成取代杂环化合物及含有该化合物的药物组合物，该化合物能够抑制或拮抗一类受体酪氨酸激酶，肌动蛋白相关激酶（Trk），特别是神经生长因子（NGF）受体TrkA。本发明进一步涉及在治疗和/或预防疼痛、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成或与失髓鞘或脱髓鞘有关的疾病、障碍或损伤，或与NGF受体TrkA异常活动有关的疾病或障碍中使用这种化合物的用途。